|
2025
|
Invention
|
Anti-cdh17 antibody, antibody-drug conjugate thereof, and use thereof. The present application re... |
|
|
Invention
|
Targeted protein degrader having inhibitory effect on kras. The present invention relates to a co... |
|
|
Invention
|
Compound having kras inhibitory effect. Provided are a compound having a KRAS inhibitory effect, ... |
|
|
Invention
|
Compound acting as cbl-b inhibitor. Disclosed are a compound having a Cbl-b inhibiting effect or ... |
|
|
Invention
|
Antibody against fibroblast growth factor receptor 2b and use thereof. The present invention rela... |
|
|
Invention
|
Anti-fgfr2b antibody, antibody-drug conjugate thereof, and use thereof. Provided are a specific b... |
|
|
Invention
|
Anti-mucin 17 antibody, conjugate thereof and use thereof. An antibody specifically binding to mu... |
|
|
Invention
|
Use of cordyceps sinensis in preparing drug for preventing and treating sepsis associated acute k... |
|
|
Invention
|
Use of egfr inhibitor. The present invention relates to use of an EGFR inhibitor in the preparati... |
|
|
Invention
|
Compound having pkmyt1 inhibition effect. The present invention provides a PKMYT1 inhibitor compo... |
|
|
Invention
|
Pharmaceutical composition of long-acting glp-1/gip dual agonist. A pharmaceutical composition co... |
|
|
Invention
|
Nasal delivery pharmaceutical composition of long-acting glp-1/gip dual agonist. Provided are a n... |
|
2024
|
Invention
|
Solid-phase synthesis method for glp-1/gip dual agonist. The present invention provides a use of ... |
|
|
Invention
|
Use of glp-1r/gipr double-target agonist in preparing animal drug. Use of a GLP-1R/GIPR double-ta... |
|
|
Invention
|
Pkmyt1 inhibitory compound and use thereof. Provided are a PKMYT1 inhibitory compound, and a phar... |
|
|
Invention
|
Kras-protac chimeric compound and use thereof. nn-KRAS ligand (I) or a pharmaceutically acceptabl... |
|
|
Invention
|
Mb-102 related compound, and preparation method therefor and use thereof. Provided are an MB-102 ... |
|
|
Invention
|
Arylamine compound having protein degradation effect. Provided in the present disclosure is a new... |
|
|
Invention
|
Compounds having ptpn2 inhibitory effects and use thereof. Disclosed are compounds having PTPN2 i... |
|
|
Invention
|
Glp1r agonist and preparation method for intermediate thereof. A GLP1R agonist and a preparation ... |
|
|
Invention
|
Cordyceps sinensis fermentation composition. A cordyceps sinensis fermentation composition, conta... |
|
|
Invention
|
Cordyceps sinensis fermentation composition. A Cordyceps sinensis fermentation composition, compr... |
|
|
Invention
|
Novel anti-fgfr2 antibodies. Provided are an anti-FGFR2b antibody or antigen-binding fragments th... |
|
|
Invention
|
Externally applied composition of minoxidil and ruxolitinib, and use thereof. Disclosed in the pr... |
|
|
Invention
|
Glp-1 receptor agonist and composition and use thereof.
Provided are a GLP-1 receptor agonist co... |
|
|
Invention
|
Glp-1/gip dual agonist, preparation method and use thereof.
The present invention relates to lon... |
|
|
Invention
|
Gip receptor agonist and use thereof.
The present invention is in the field of biomedical techno... |
|
|
Invention
|
Gip receptor agonist and use thereof. Disclosed are a peptide compound having an agonistic activi... |
|
2023
|
Invention
|
Oxime-containing compound having sting inhibitory effect, pharmaceutical composition thereof, and... |
|
|
Invention
|
Kras-protac chimeric compound, preparation method therefor and use thereof. The present invention... |
|
|
Invention
|
Protac chimeric compound, preparation method therefor and use thereof. A compound represented by ... |
|
|
Invention
|
Novel crystal form of glp-1 receptor agonist, method for preparing same, pharmaceutical compositi... |
|
|
Invention
|
Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutic... |
|
|
Invention
|
Antibody targeting cd112r or antigen-binding fragment thereof and use thereof. The present applic... |
|
|
Invention
|
1,5-naphthyridine cgas inhibitor and use thereof. 00) and a pharmaceutically acceptable salt ther... |
|
|
Invention
|
Glp-1 receptor agonist and composition and use thereof. Provided are a GLP-1 receptor agonist com... |
|
|
Invention
|
Amide compound having sting inhibitory effect, and pharmaceutical composition and use thereof. A ... |
|
|
Invention
|
Compound having kras g12d inhibitory effect. Disclosed are a compound as represented by formula (... |
|
|
Invention
|
Protac chimeric compound, preparation method therefor and use thereof. Disclosed are a chimeric c... |
|
|
Invention
|
Glp-1/gip dual agonist, and preparation method therefor and use thereof. A long-acting GLP-1/GIP ... |
|
|
Invention
|
Novel anti-fgfr2 antibodies. Disclosed are anti-FGFR2b antibody or antigen-binding fragments ther... |
|
|
Invention
|
Ror1-targeted binding molecule and use thereof.
The present application relates to antibodies th... |
|
|
Invention
|
Ror1-targeted binding molecule and use thereof. The present application relates to an antibody sp... |
|
2022
|
Invention
|
Ruxolitinib composition and preparation method therefor.
Disclosed in the present invention is a... |
|
|
Invention
|
Solid composition of glp-1 receptor agonist.
Provided in the present invention is a pharmaceutic... |
|
|
Invention
|
Thiophene glp-1 receptor agonist and use thereof.
Provided are a series of thiophene GLP-I recep... |
|
2021
|
Invention
|
Fermentation method for mupirocin.
A fermentation method for mupirocin, the method comprising pe... |
|
|
Invention
|
Benzimidazolone glp-1 receptor agonist and use thereof.
A benzimidazolone GLP-1 receptor agonist... |
|
|
Invention
|
Method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and synthetic intermediate thereof... |
|
|
Invention
|
Method for extracting mupirocin.
A method for extracting mupirocin. The main steps thereof compr... |
